| Dataset:21148492 Search Result |
|
|
|
|
|
|
|
|
| Clinical
Information |
|
|
|
|
|
|
|
|
| Table 1.
Clinical and Virological Background of the 10 Cases involved in the
Oseltamivir-Resistant (H1N1) 2009 Virus Outbreak, University Hospital of
Wales, Cardiff, United Kingdom |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Case |
Age |
Underlying Condition |
Admission |
Reason for admission |
Length of admission |
Date of first Influenza PCR
Positive |
Date of sample positive
with H275Y mutation |
Minimum time of viral
shedding |
Treatment |
Other information |
| 1 |
19 |
Acute Lymphoblastic leukemia |
10/18/09 |
ILI |
1 day |
10/18 (Oseltamivir sensitive) |
N/A |
N/A |
5 days
oseltamivir (75 mg/BD) |
Admitted for sampling Recovered |
| 2 |
26 |
Acute myeloid leukemia |
10/11/09 |
Fever |
40 days (transferred to ICU 11/05) |
10/29(Oseltamivir
sensitive) |
11/04 (70% H275Y) (result
available for clinician 11/12) |
30 days |
5 days oseltamivir (75
mg/BD), 4 days oselta- mivir (150 mg/ BD), 10 days intravenous zanamivir |
Recovered |
| 3 |
52 |
Mantle cell lymphoma |
10/25/09 |
Induction chemotherapy |
7 days readmitted 11/09 for 6 days |
10/30 (Oseltamivir sensitive) |
11/05 (86% H275Y)(result
available for clinician 11/12) |
12 days |
5 days oseltamivir (75
mg/BD), stop- ped treatment 1 day, 10 days oseltamivir (150 mg/BD) 1 inhaled
zanamivir |
Recovered |
| 4 |
56 |
Multiple myeloma |
10/28/09 |
Consolidation chemotherapy |
8 days |
11/02 (Oseltamivir sensitive) |
No evidence of H275Y muta-
tion in repeat samples |
5 days |
5 days oseltamivir (75
mg/BD) |
Earlier sample 10/30 negative Recovered |
| 5 |
48 |
Multiple |
10/29/09 |
Fever |
25 days |
11/07 (Oseltamivir resistant) |
11/07 (100% H275Y) (result
available for clinician 11/19) |
23 days |
3 days Oseltamivir (75
mg/BD), 9 days oseltamivir (150 mg/BD), 1 day oseltamivir (150 mg/BD) 1
inhaled 4 days inhaled zanamivir, |
Recovered |
| 6 |
27 |
Non-Hodgkin lymphoma |
10/25/09 |
Induction chemotherapy |
24 days |
11/09 (oseltamivir
sensitive), Negative PCR 11/17 |
Viral rebound 11/19 (100%
H275Y)(result available for clinician 11/26) |
10 days |
10 days Oseltamivir
(150 mg/BD) |
Recovered |
| 7 |
48 |
Burkitt’s lymphoma |
11/02/09 |
Consolidation chemotherapy |
9 days readmitted 11/13 for
14 days
|
11/09 (Oseltamivir resistant) |
11/09 (100% H275Y)(result
available for clinician 11/19) |
20 days |
5 days Oseltamivir (150 mg/
BD), 3 days oseltamivir (150 mg/BD) 1 inhaled zanamivir, 10 days
intravenous |
Recovered |
| 8 |
45 |
Acute myeloid leukemia |
10/24/09 |
Induction chemotherapy |
25 days |
11/09 (Oseltamivir resistant) |
11/09 (Oseltamivir
resistant available for clinician 11/19) |
6 days |
10 days oseltamivir (150
mg/BD) |
Earlier sample 11/02 negative Recovered |
9
|
74 |
Acute myeloid leukemia |
10/26/09 |
Perianal abscess |
11 days readmitted 11/16 |
11/17 (Oseltamivir resistant) |
11/17(100% H275Y) (result
available for clinician 11/19) |
22 days |
2 days oseltamivir (150
mg/BD), 8 day oseltamivir (150 mg/BD) 1 inhaled zanamivir 2 days intravenous
zanamivir |
Readmitted with ILI Recovered |
| 10 |
68 |
Chronic lymphocytic leukemia |
11/05/09 |
Expressive dysphasia, poor coordination |
>25 days |
11/20 (Oseltamivir resistant) |
11/20 (100% H275Y) (result
available 11/26) |
10 days |
Oseltamivir prophylaxis
from 11/ 10, 10 days Oseltamivir (150 mg/BD) 1 inhaled zanamivir |
Earlier sample 11/07 negative Recovered |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|